Patient disposition. Notably, also some patients with PD at EoT have entered the FU period. ∗All the patients randomized were included in efficacy analysis (FAS) and safety analysis. ^†Discontinuations of other study components not shown. ^‡Completed study: all FU visits completed. ^§PD and participation in another clinical trial. AE, adverse event; COVID-19, coronavirus disease 2019; FU, follow-up; PD, progressive disease.